Ally Financial Inc. Abb Vie Inc. Transaction History

Ally Financial Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$154.79 - $180.76 $4.64 Million - $5.42 Million	30,000 New	30,000 $5.15 Million
Q4 2023 Feb 13, 2024	SELL	$137.6 - $154.97 $3.44 Million - $3.87 Million	-25,000 Reduced 55.56%	20,000 $3.1 Million
Q3 2023 Nov 13, 2023	BUY	$133.59 - $154.65 $3.34 Million - $3.87 Million	25,000 Added 125.0%	45,000 $6.71 Million
Q2 2023 Aug 11, 2023	BUY	$132.51 - $164.9 $1.19 Million - $1.48 Million	9,000 Added 81.82%	20,000 $2.69 Million
Q2 2022 Aug 10, 2022	BUY	$137.62 - $174.96 $1.51 Million - $1.92 Million	11,000 New	11,000 $1.69 Million
Q1 2022 May 13, 2022	SELL	$131.98 - $163.75 $7.57 Million - $9.39 Million	-57,320 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $1.27 Million - $1.7 Million	17,320 Added 43.3%	57,320 $5.63 Million
Q1 2020 May 14, 2020	BUY	$64.5 - $97.79 $645,000 - $977,900	10,000 Added 33.33%	40,000 $3.05 Million
Q4 2019 Feb 13, 2020	BUY	$72.13 - $90.25 $1.08 Million - $1.35 Million	15,000 Added 100.0%	30,000 $2.66 Million
Q1 2018 May 14, 2018	BUY	$92.01 - $123.21 $1.38 Million - $1.85 Million	15,000 New	15,000 $1.42 Million

3,843

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $294B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Ally Financial Inc., based on Form 13F filings with the SEC.

Stay updated on Ally Financial Inc. with notifications on news.